News Wales takes UK lead on needle-free anaphylaxis prevention Wales has recommended ALK's EURneffy nasal spray as a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis.
News First-in-class hay fever immunotherapy backed for NHS use A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.
News First intranasal anaphylaxis drug launches in Germany An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first market, by ALK-Abello.
News Dust mite allergy sufferers set for a new NHS treatment ALK-Abello's Acarizax for dust mite allergy should soon be available through the NHS in England, Wales and Northern Ireland, but not in Scotland.
News FDA clears Sanofi's Type 3 Gaucher therapy Infilbray Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.